Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Eduardo Vilar et al.|Annals of Oncology|2018Cited by 239
Survival improvement for patients with metastatic colorectal cancer over twenty yearsFadl A. Zeineddine, John Paul Shen, Mohammad A. Zeineddine et al.|npj Precision Oncology|2023Cited by 172
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer.Van K. Morris, Scott Kopetz, Christine M. Parseghian et al.|Journal of Clinical Oncology|2022Cited by 78
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitorsJakob M. Riedl, Ryan B. Corcoran, Ferran Fece de la Cruz et al.|Annals of Oncology|2025Cited by 49